Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
Rhea-AI Summary
Tempest (Nasdaq: TPST) will present clinical updates for its dual-targeting CAR-T candidate TPST-2003 at ISCT 2026 in Dublin, May 6-9. Data include REDEEM-1 Phase 1/2a interim results showing a 100% complete response rate among six then-evaluable patients per IMWG criteria and a reported favorable safety profile. Presentations include an oral talk (May 6) and poster reception (May 7).
AI-generated analysis. Not financial advice.
Positive
- Interim 100% complete response rate among six efficacy-evaluable patients (IMWG criteria)
- Favorable safety profile reported alongside efficacy in interim REDEEM-1 data
- Oral presentation and poster at ISCT 2026, increasing scientific visibility
Negative
- Efficacy result is interim and based on a very small sample: six then-evaluable patients
- Data are from an ongoing Phase 1/2a study and require replication in the remainder of REDEEM-1 and a registrational trial
News Market Reaction – TPST
On the day this news was published, TPST gained 2.96%, reflecting a moderate positive market reaction. Argus tracked a peak move of +17.6% during that session. Our momentum scanner triggered 22 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $854K to the company's valuation, bringing the market cap to $29.69M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
While TPST was down 1.74% pre-release, momentum peers BRNS, RADX and PSTV all showed single- to low-double-digit gains, pointing to stock-specific dynamics rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 22 | Manufacturing milestone | Positive | +4.5% | Delivered TPST-2003 vector to AGCTC, enabling pivotal-phase manufacturing work. |
| Apr 14 | Leadership hire | Positive | +5.1% | Appointed head of business development to drive partnering and licensing strategy. |
| Mar 30 | Earnings and update | Negative | -12.1% | Reported lower cash, sizeable net loss and R&D spend alongside pipeline updates. |
| Mar 23 | Private placement | Negative | -19.6% | Announced up to $6M private placement with warrants and new share issuance. |
| Mar 11 | Partnership deal | Positive | +0.0% | Selected AGCTC for TPST-2003 tech transfer and REDEEM-1 efficacy update. |
Recent TPST news has generally aligned with price reactions, with positive CAR-T and business updates seeing gains and financing-related or heavier financial disclosures drawing selling.
Over the last several months, Tempest has focused on advancing TPST-2003 and strengthening its platform. A Mar 11 partnership and a Apr 22 manufacturing milestone highlighted 100% response rates in REDEEM‑1 and supported plans for a potential registrational study. Corporate developments included a Mar 23 private placement of up to $6M and the Mar 30 2025 results detailing a $26.3M net loss and $7.7M cash. The current ISCT clinical update continues this emphasis on TPST‑2003’s dual‑targeting CAR‑T profile.
Regulatory & Risk Context
An effective Form S-3 dated Apr 1, 2026 registers the resale of up to 2,777,781 shares issued in a March 20, 2026 private placement. These are selling stockholder shares; Tempest states it will not receive proceeds from their resale, though warrant exercises could still bring cash to the company.
Market Pulse Summary
This announcement highlights Tempest’s plan to present updated TPST‑2003 data at ISCT 2026, including previously reported 100% complete responses in 6 efficacy‑evaluable REDEEM‑1 patients with relapsed/refractory multiple myeloma. The focus on dual‑targeting CD19/BCMA CAR‑T and extramedullary disease reinforces TPST‑2003 as a central asset. In context, recent milestones, ongoing Phase 1/2a development, and an effective Form S‑3 resale registration for 2,777,781 shares are key elements for tracking the program’s and company’s trajectory.
Key Terms
car-t medical
chimeric antigen receptor t-cell medical
extramedullary disease medical
relapsed/refractory multiple myeloma medical
phase 1/2a medical
international myeloma working group medical
immunotherapy medical
AI-generated analysis. Not financial advice.
- Presentation will showcase recent data from multiple clinical studies evaluating dual-targeting CD19/BCMA CAR-T therapy candidate TPST-2003
- Results support clinical benefit of parallel-structure dual-targeting CAR architecture in patients with relapsed/refractory multiple myeloma
- Data further support potential of TPST-2003 to improve outcomes for patients with extramedullary disease
BRISBANE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”) will present its most recent clinical data from its lead dual-targeting chimeric antigen receptor T-cell (“CAR-T”) therapy product candidate, TPST-2003, at the International Society for Cell & Gene Therapy (“ISCT”) Scientific Annual Meeting in Dublin, May 6-9, 2026. Updates will include the latest data from the ongoing REDEEM-1 Phase 1/2a trial evaluating TPST-2003, as well as progress in Tempest’s other dual-targeting CAR-T pipeline programs.
Earlier this year, Tempest announced positive interim data from REDEEM-1, including a
“We look forward to sharing the latest results from REDEEM-1 and updates on our other dual-targeting CAR-T programs at ISCT,” said Dr. Matt Angel, President and Chief Executive Officer of Tempest. “We believe that the results that we announced earlier this year suggest that TPST-2003 could offer a safe, effective option for patients with relapsed/refractory multiple myeloma (“rrMM”), and we continue to believe that replicating these results in the remainder of the REDEEM-1 trial and in a registrational trial would position TPST-2003 as a class-leading therapy for rrMM.”
Presentation Details
REDEEM-1, a multicenter open-label Phase 1/2a study of a BCMA/CD19 dual-targeting CAR-T therapy in patients with relapsed/refractory multiple myeloma including those with extramedullary disease. Abstract #1268. Oral Presentation, May 6, 2026 (12:00-13:00 GMT) & Poster Reception, May 7, 2026 (18:00-19:30 GMT), Immunotherapy Session. Presenter: Dr. Matt Angel.
About TPST-2003
TPST-2003 is an autologous CD19/BCMA dual-targeting CAR-T therapy designed to improve response depth and durability in patients with relapsed/refractory multiple myeloma (“rrMM”) through a parallel dual-targeting CAR structure designed to address tumor heterogeneity and antigen escape. TPST-2003 is being developed in China by Tempest’s partner, Novatim Immune Therapeutics (“Novatim”). Under its agreement with Novatim, Tempest has the exclusive right to develop TPST-2003 outside of China, India, Turkey, and Russia.
About REDEEM-1
REDEEM-1 (Study nos. CTR20233309/NCT06223646) is a Phase 1/2a clinical trial evaluating TPST-2003 in patients with relapsed/refractory multiple myeloma, including patients with high-risk cytogenetics and patients with extramedullary disease. The REDEEM-1 trial has a targeted full enrollment of 29 patients. The REDEEM-1 trial is sponsored and being conducted by Tempest’s partner, Novatim Immune Therapeutics, with a total of eight clinical sites registered in China: Peking Union Medical College Hospital (Dr. Jian Li; lead site), The First Affiliated Hospital of Nanchang University (Dr. Fei Li), Peking University First Hospital (Dr. Yujin Dong), Henan Cancer Hospital (Dr. Baijun Fang), Shanxi Provincial Cancer Hospital (Dr. Liping Su), The Second Xiangya Hospital of Central South University (Dr. Hongling Peng), The First Affiliated Hospital of China Medical University (Dr. Xiaojing Yan), and The Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College (Dr. Dehui Zou).
Additional Clinical Trials Evaluating TPST-2003
A Phase 1/2 IIT (Study no. NCT04714827) is evaluating TPST-2003 in patients with relapsed/refractory multiple myeloma, including patients with high-risk cytogenetics and patients with extramedullary disease. The IIT is sponsored and being conducted by Tempest’s partner, Novatim, with a total of two clinical sites registered in China: Shanghai Fourth People’s Hospital (Dr. Weijun Fu; lead site) and Shanxi Provincial Cancer Hospital (Dr. Liping Su).
A Phase 1 trial (Study nos. CTR20242409/NCT06518876) is evaluating TPST-2003 in patients with POEMS, a rare blood disorder caused by abnormal plasma cells. The Phase 1 trial is sponsored and being conducted by Tempest’s partner, Novatim, with a total of three clinical sites registered in China: Peking Union Medical College Hospital (Dr. Jian Li; lead site), Xuanwu Hospital Capital Medical University (Dr. Wanling Sun), and West China Hospital, Sichuan University (Dr. Yu Wu).
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at https://www.tempesttx.com.
Forward-Looking Statements
This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, concerning Tempest Therapeutics, Inc. These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Tempest Therapeutics, as well as assumptions made by, and information currently available to, management of Tempest Therapeutics. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “could”, “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “goal”, “suggest”, “target” and other similar expressions. All statements that are not historical facts are forward-looking statements, including but not limited to, statements regarding: Tempest Therapeutics’ plan to present data from clinical trials, including the REDEEM-1 trial; the design, initiation, progress, timing, scope and results of clinical trials; the planned advancement of a diversified next-generation CAR-T pipeline; anticipated therapeutic benefit and regulatory development of Tempest Therapeutics’ product candidates, including TPST-2003; and Tempest Therapeutics’ ability to achieve its operational plans. All forward-looking statements in this press release are based on Tempest Therapeutics’ current expectations, estimates and projections about its industry as well as management’s current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to Tempest Therapeutics’ need for additional capital to fund its planned programs and operations and to continue to operate as a going concern; unexpected safety or efficacy data observed during preclinical or clinical trials; the possibility that results from prior clinical trials and preclinical studies may not necessarily be predictive of future results; past results may not be indicative of future results; clinical trial site activation or enrollment rates that are lower than expected; loss of key personnel; changes in expected or existing competition; changes in the regulatory environment; risks relating to volatility and uncertainty in the capital markets for biotechnology companies; and unexpected litigation or other disputes. These and other factors that may cause actual results to differ from those expressed or implied are discussed in greater detail in the “Risk Factors” section of Tempest Therapeutics' Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 30, 2026, and in other documents filed by Tempest Therapeutics from time to time with the SEC. Except as required by applicable law, Tempest Therapeutics undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Tempest Therapeutics’ views as of any date subsequent to the date of this press release and should not be relied upon as prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Tempest Therapeutics.
Investor Contacts:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
